Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Monika ZurkovaEva KriegovaVitezslav KolekVladimira LostakovaMartina SterclovaVladimir BartosMartina DoubkovaIlona BinkovaMichal SvobodaJana StrenkovaMarketa JanotovaMartina PlackovaLadislav LacinaVladimir RihakFrantisek PetrikPavlina LisaRadka BittenglovaRichard TylGustav OndrejkaHana SuldovaJaroslav LnenickaJana PsikalovaTomas SnizekJiri HomolkaRenata KralovaJan KervitzerMartina Vasakovanull nullnull nullPublished in: Respiratory research (2019)
Our study observed the 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient's IPF cohort. DLCO decline of ≥10% shows a potential as a mortality predictor in IPF patients on pirfenidone, and should be routinely evaluated during follow-up examinations.